Skip to main content
. 2019 Nov 1;18(6):4625–4630. doi: 10.3892/etm.2019.8163

Figure 1.

Figure 1.

Tumor responses at different follow-up time-points. (A) 3 months post-dTACE (n=90); (B) 6 months post-dTACE (n=88); (C) 1 year post-dTACE (n=51); (D) 2 years after dTACE (n=15). *P<0.05 vs. PD at the same juncture. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; dTACE, drug-eluting bead transarterial chemoembolization; Y, year; M, month.